Scope
ACG separates incidental focal liver lesions by imaging diagnosis and malignant or bleeding potential. Most lesions in people without liver-disease risk are benign, but an uncertain lesion needs appropriate multiphasic imaging and sometimes multidisciplinary review. Adenoma, focal nodular hyperplasia, haemangioma and cysts have different follow-up and intervention rules.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Characterize the lesion before choosing a pathway
- Assess prior cancer, constitutional symptoms, hormone or steroid exposure, chronic-liver-disease and metabolic risk, relevant blood tests and imaging. A lesion in a patient with cirrhosis or malignancy risk requires a different interpretation from an incidental lesion in a normal liver. [1]
- For uncertain lesion aetiology, obtain multiphasic contrast-enhanced MRI or CT with late arterial, portal-venous and delayed phases. Refer atypical or inadequately characterized lesions for multidisciplinary liver-tumour review; a routine single-phase scan may not be sufficient. [1]
Manage adenoma by size, sex and malignant potential
- For hepatic adenoma, discontinue oral contraceptives or hormone-impregnated intrauterine devices; encourage weight loss when overweight or obese. The weight-loss recommendation is conditional and no specific regression target is established. [1]
- Use multiphasic imaging, preferably MRI, to distinguish adenoma from other lesions. An atypical appearance or changes concerning for malignant transformation warrant biopsy assessment; routine biopsy solely for subtyping an adenoma below 5 cm in a woman is not recommended. [1]
- In women with adenoma below 5 cm, discontinue exogenous hormones, address excess weight and consider contrast-enhanced surveillance every 6 months for 2 years, then annually. Suspicious subtype or malignant features change this conservative pathway. [1]
- For women with adenoma at least 5 cm, modify risks and observe for 6–12 months, then resect if it has not regressed below 5 cm. Do not use the observation period when imaging suggests malignancy. Continued surveillance is needed after regression. [1]
- Consider resection of adenoma in men regardless of size because malignant transformation risk is higher. β-catenin-mutated adenomas should be resected regardless of size; these rules must not be replaced by the small-lesion surveillance pathway used for lower-risk women. [1]
- If an adenoma requires treatment but resection is unsuitable, consider embolization or ablation. For rupture, stabilize haemodynamics first, followed by embolization and/or resection. These are conditional recommendations with low or very-low certainty. [1]
- Monitor hepatic adenoma regularly during pregnancy; growth beyond 6.5 cm or high-risk features for haemorrhagic rupture warrant treatment assessment. Lesions concerning for malignant transformation require a malignant-lesion management approach, not routine benign-adenoma follow-up. [1]
Avoid unnecessary intervention for confirmed FNH
- For suspected focal nodular hyperplasia, consider multiphase MRI with hepatobiliary-specific contrast to distinguish it from adenoma. Imaging can usually establish the diagnosis without biopsy. Do not routinely stop oral contraceptives solely because FNH is present. [1]
- Once FNH is confidently confirmed on imaging, no further follow-up is required and growth alone does not require resection. If symptoms prompt consideration of surgery, explain that symptoms may persist because FNH rarely causes them. [1]
Confirm haemangioma and retain high-risk exceptions
- A well-defined echogenic avascular lesion smaller than 2 cm can be diagnosed as haemangioma by ultrasound only in a normal liver without relevant medical history, liver-disease risk or malignancy risk. Otherwise obtain multiphasic contrast imaging; uncertain cases need monitoring and multidisciplinary review. [1]
- Avoid biopsy of a suspected haemangioma when possible because of bleeding risk. Confirmed haemangioma generally needs no follow-up unless cirrhosis or another malignancy risk is present. For a suspected haemangioma in cirrhosis or chronic hepatitis B meeting HCC-surveillance criteria, continue imaging every 3–6 months for at least one year. [1]
- Asymptomatic large cavernous haemangioma does not itself require resection. Complications such as rupture, internal bleeding, consumptive coagulopathy or compression can justify intervention; discuss alternatives at a specialist board if surgery is unsuitable. [1]
Separate simple cysts from complex and polycystic disease
- An asymptomatic simple hepatic cyst needs neither routine surveillance nor intervention, regardless of size. Septations, mural thickening or nodularity, calcification, heterogeneity or daughter cysts on ultrasound require CT or MRI characterization rather than reassurance as a simple cyst. [1]
- For a symptomatic simple cyst, consider surgical fenestration or aspiration with sclerotherapy. An asymptomatic complex cyst should be discussed at a multidisciplinary board, with consideration of repeat imaging in 6–12 months rather than applying the no-follow-up simple-cyst rule. [1]
- In polycystic liver disease, aim treatment at symptom relief and quality of life. Consider stopping exogenous oestrogen in women; select cyst-directed intervention according to cyst characteristics, liver reserve and centre expertise. [1]
- Use somatostatin analogues for numerous small or medium polycystic lesions not amenable to resection, fenestration or aspiration-sclerotherapy, or for symptomatic ADPKD with concurrent polycystic liver disease. Refractory symptoms from a major cyst burden can warrant transplant assessment, with or without kidney transplantation. [1]
- For suspected mucinous cystic neoplasm, aspiration or biopsy cannot reliably distinguish benign from malignant cysts and is not recommended for that purpose. Thick septations, nodules, calcifications or mixed solid-cystic features require prompt evaluation for complete resection; nonsurgical candidates need surveillance and specialist review of change. [1]
- Biliary hamartomas and peribiliary cysts do not require surveillance. Intraductal papillary bile-duct neoplasms are premalignant and require continued surveillance even after resection; choledochal-cyst decisions depend on cyst type and malignant potential. [1]
Use specialist pathways for hydatid cysts
- Consider surgery for complicated hydatid cysts when feasible, including biliary communication, multiseptation, rupture, haemorrhage, secondary infection or percutaneous inaccessibility. For uncomplicated cysts when surgery is not an option, consider puncture-aspiration-scolicidal injection-reaspiration with adjunct antihelminthic therapy. [1]
- For symptomatic or active hydatid cysts proceeding to surgery or puncture, antihelminthic treatment is indicated beforehand to reduce recurrence or secondary seeding risk. These recommendations do not provide a complete stage-specific echinococcosis protocol. [1]
Limitations and use
- This summary focuses on common benign solid and cystic lesions and selected hydatid guidance. It is not a complete HCC, cholangiocarcinoma, metastatic, vascular-malignancy or transplant-selection pathway; high-risk liver lesions require the relevant specialist guidance.
- Formal recommendations and expert key concepts have different evidence status. The summary does not supply procedural technique, medication doses, detailed adenoma pregnancy imaging schedules or complete parasite-stage eligibility for intervention.
- The hydatid section reflects this ACG edition and does not establish that every echinococcal cyst requires treatment. Use current stage-specific specialist guidance before puncture, surgery or medical treatment.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Liver: Focal Liver Lesions
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.